Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 2, 1997, Pages 139-141

  Levine, John E ^a   Cohen, Alan ^a   MacQueen, Marji ^a   Martin, Marie ^a   Giardina, Patricia J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chelation; Deferoxamine; Hemoglobinopathies; Key Words; Neurotoxicity

Indexed keywords

DEFEROXAMINE;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CASE REPORT; CHELATION; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; IRON OVERLOAD; NEUROTOXICITY; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; SPLENECTOMY; TREATMENT PLANNING;

ADULT; BETA-THALASSEMIA; DEFEROXAMINE; FEMALE; HUMANS; MOTOR NEURON DISEASE; SIDEROPHORES;

EID: 0030968671     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199703000-00008     Document Type: Article

References (12)

1. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-5.
2. Cohen AR, Martin M, Schwartz E. Current treatment of Cooley's anemia: intravenous chelation therapy. Ann NY Acad Sci 1990;612:286-92.
3. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992;339:699-701.
4. Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:1077-80.
5. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2:181-4.
6. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-73.
7. Styles LA, Vichinsky EP. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. J Pediatr Hematol Oncol 1996;18:42-5.
8. Bentur Y, Koren G, Tesoro A, Carley H, Olivieri N, Freedman MH. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin Pharmacol Ther 1990;47:478-82.
9. Klebanoff SJ, Waltersdorph AM, Michel BR, Rosen H. Oxygenbased free radical generation by ferrous ions and deferoxamine. J Biol Chem 1989;264:19765-71.
10. Borg DC, Schaich KM. Prooxidant action of desferrioxamine: Fenton-like production of hydroxyl radicals by reduced ferrioxamine. J Free Radic Biol Med 1986;2:237-43.
11. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989;73:403-9.
12. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-7.